urpose: The medium-risk (IR) prostate cancer (PCa) are a heterogeneous group in terms of prognosis. For unfavorable or favorable IR PCa treated with radiotherapy, the
Antibodies Assay Kits Biology Cells cDNA Clia Kits Culture Cells Devices DNA DNA Templates DNA Testing Elisa Kits Enzymes Equipments Exosomes Gels Isotypes Medium & Serums NATtrol Panel Particles PCR Pcr Kits Peptides Reagents Recombinant Proteins Ria Kits RNA Test Kits Uncategorized Vector & Virus Western Blot